<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609490</url>
  </required_header>
  <id_info>
    <org_study_id>Zhaoke-201505-Azilsartan</org_study_id>
    <nct_id>NCT02609490</nct_id>
  </id_info>
  <brief_title>Azilsartan in Chinese Patients With Mild and Moderate Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3 clinical study to evaluate the safety and efficacy of Azilsartan in Chinese
      hypertension patients
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of sitting diastolic blood pressure at week 16</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting diastolic blood pressure at week 8</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting systolic blood pressure at week 8</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting diastolic blood pressure at week 2</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting diastolic blood pressure at week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting diastolic blood pressure at week 12</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting systolic blood pressure at week 2</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting systolic blood pressure at week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of sitting systolic blood pressure at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decrease of 24-hour ambulatory blood pressure monitoring at week 16</measure>
    <time_frame>16 week</time_frame>
    <description>do a 24-hour ambulatory blood pressure monitoring at baseline and at week 16, compare the decrease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Safety and Efficacy og Azilsartan in Chinese Hypertension Patients</condition>
  <arm_group>
    <arm_group_label>Treatment-Azilsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan tabelts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control-olmesartan medoxomil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olmesartan medoxomil tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan tablets</intervention_name>
    <description>20mg/tablet</description>
    <arm_group_label>Treatment-Azilsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan placebo tablets</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Positive Control-olmesartan medoxomil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil tablets</intervention_name>
    <description>20mg/tablet</description>
    <arm_group_label>Positive Control-olmesartan medoxomil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil placebo tablets</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Treatment-Azilsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-70 years of age (including 18 and 70 years of age), male or female;

          2. diagnosed with mild to moderate essential hypertension;

          3. clinic diastolic and systolic blood pressure need to meet the following two
             conditions: 3 times mean sitting diastolic blood pressure measurements at
             95mmHg-110mmHg (not including 110mmHg); 3 times sitting systolic blood pressure
             measured and mean value between150mmHg-180mmHg (not including 180mmHg);

          4. understand clearly that voluntary to participate in the study, sign informed consent.

        Exclusion Criteria:

          1. severe essential hypertension (sitting systolic ≥180mmHg and / or sitting diastolic
             pressure ≥110mmHg), malignant hypertension, hypertensive emergency, hypertensive
             crisis and high blood pressure encephalopathy.

          2. secondary hypertension.

          3. The following hypertension and diseases: acute myocardial infarction within 6 months,
             the cerebral artery accident, transient ischemic attack; or dissecting aortic
             aneurysm, angina, II-IVClass (NYHA classification) history of heart failure Ⅱ degree
             atrioventricular block, sick sinus integrated disease, bradycardia (heart rate &lt;50
             beats / min) or other antiarrhythmic drugs needed.

          4. significant laboratory abnormalities include: serum potassium&gt; 5.5mmol / L; blood ALT
             or AST&gt; 2.5ULN; serum creatinine&gt; 1.5ULN.

          5. unilateral or bilateral renal artery stenosis.

          6. Type 1 diabetes and poor glycemic control of type 2 diabetes (HbA1c values ≥ 8%).

          7. gastrointestinal lesions or gastrointestinal surgery may affect drug absorption or
             excretion, such as stomach-bowel resection, nearly one year activity of
             gastrointestinal inflammation, ulcers or gastrointestinal bleeding.

          8. azilsartan sheet or olmesartan medoxomil tablets and related drugs (ARB, ACEI And
             renin inhibitors) allergies.

          9. pregnant, lactating female patients, or during the test does not guarantee the
             effective collision pregnant person.

         10. Obesity, body mass index (BMI)&gt; 30kg / m2.

         11. Import of use in addition to import other types of medication trials of
             antihypertensive drugs, Anti-angina drugs, lithium agents, corticosteroids, licorice,
             estrogen, digitalis Drugs and drugs were potassium.

         12. Variance of diastolic blood pressure ≥8mmHg.

         13. drug or alcohol abuse within 6 months Are drinking more than two units of alcohol (1
             unit = 360mL or 45mL alcohol content of 40%).

        14 patients with malignant tumors. 15. hemodialysis patients or strictly limit salt
        therapy. 16. Participated in other clinical trials within 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Huo, MD</last_name>
    <phone>+86-10-83572211</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>baowei Zhang, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First hospiatl</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Huo, M.D. Ph. D.</last_name>
      <phone>+86-10-83572211</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

